Acorda Therapeutics (ACOR) Receiving Somewhat Favorable Press Coverage, Analysis Finds

News stories about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.6241854967686 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Acorda Therapeutics (ACOR) traded up 0.46% during trading on Friday, hitting $21.90. The stock had a trading volume of 421,807 shares. The stock has a 50 day moving average price of $21.14 and a 200-day moving average price of $20.38. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00. The stock’s market capitalization is $1.02 billion.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.16. The business had revenue of $139.40 million for the quarter, compared to analyst estimates of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. Acorda Therapeutics’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 EPS. On average, equities research analysts predict that Acorda Therapeutics will post $1.71 earnings per share for the current year.

ACOR has been the topic of a number of recent analyst reports. BidaskClub lowered Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 13th. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a research note on Friday, July 28th. TheStreet lowered Acorda Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, April 24th. Jefferies Group LLC initiated coverage on Acorda Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $22.00 price objective on the stock. Finally, J P Morgan Chase & Co set a $24.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research note on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, six have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $25.26.

TRADEMARK VIOLATION NOTICE: “Acorda Therapeutics (ACOR) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at

In related news, insider Ron Cohen bought 20,000 shares of the business’s stock in a transaction on Friday, June 16th. The shares were purchased at an average cost of $16.95 per share, with a total value of $339,000.00. Following the acquisition, the insider now owns 511,648 shares of the company’s stock, valued at $8,672,433.60. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Barry E. Greene sold 10,000 shares of Acorda Therapeutics stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $21.57, for a total value of $215,700.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $215,700. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

What are top analysts saying about Acorda Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit